Sign In
Buy DYN
$25.18
-0.550 (-2.14%)
At Close: Jul 31, 2026
Jason Rhodes Sells 272,049 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock
04:16am, Friday, 24'th Apr 2026
Dyne Therapeutics, Inc. (NASDAQ: DYN - Get Free Report) Director Jason Rhodes sold 272,049 shares of the stock in a transaction on Monday, April 20th. The shares were sold at an average price of $20.0
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 23'rd Apr 2026
WALTHAM, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically drive
Darwin Wealth Management LLC Sells 58,250 Shares of Dyne Therapeutics, Inc. $DYN
04:46am, Thursday, 09'th Apr 2026
Darwin Wealth Management LLC decreased its stake in shares of Dyne Therapeutics, Inc. (NASDAQ: DYN) by 33.6% in the undefined quarter, according to its most recent 13F filing with the SEC. The firm ow
Aberdeen Group plc Purchases 551,412 Shares of Dyne Therapeutics, Inc. $DYN
03:07am, Monday, 06'th Apr 2026
Aberdeen Group plc raised its position in Dyne Therapeutics, Inc. (NASDAQ: DYN) by 99.0% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange C
Head-To-Head Analysis: MediWound (NASDAQ:MDWD) & Dyne Therapeutics (NASDAQ:DYN)
01:13am, Friday, 03'rd Apr 2026
Dyne Therapeutics (NASDAQ: DYN - Get Free Report) and MediWound (NASDAQ: MDWD - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses bas
- Poster on previously shared positive results from DELIVER clinical trial in Duchenne muscular dystrophy (DMD) contextualizes observed clinical measures of functional improvement for managed care exp
Dyne Therapeutics (NASDAQ:DYN) Stock Price Up 4.4% – Here’s Why
05:24am, Sunday, 22'nd Mar 2026
Dyne Therapeutics, Inc. (NASDAQ: DYN - Get Free Report)'s share price rose 4.4% during mid-day trading on Friday. The company traded as high as $18.39 and last traded at $18.5840. Approximately 898,53
Dyne Therapeutics, Inc. (DYN) Presents at TD Cowen 46th Annual Health Care Conference Prepared Remarks Transcript
03:27pm, Monday, 09'th Mar 2026
Dyne Therapeutics, Inc. (DYN) Presents at TD Cowen 46th Annual Health Care Conference Prepared Remarks Transcript
Dyne Therapeutics: Strong DELIVER Data Strengthens The Bull Case
01:30pm, Monday, 09'th Mar 2026
Dyne Therapeutics maintains a strong $1.1B cash position, funding operations into mid-2028 despite heavy R&D and operating expenses in 2025. Encouraging long-term cardiopulmonary data from the DELIVER
Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)
06:01pm, Sunday, 08'th Mar 2026
- HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1 - - 48-week trial will enroll approximately 150 individuals, and first sites are now open for enrol
- New analyses out to 24-months showed improvement in heart and lung function compared to expected declines in DMD natural history - - Data expand on previously reported results demonstrating that z-r
Dyne Therapeutics (NASDAQ:DYN) Stock Price Down 6.6% on Disappointing Earnings
01:04am, Tuesday, 03'rd Mar 2026
Dyne Therapeutics, Inc. (NASDAQ: DYN - Get Free Report)'s stock price dropped 6.6% during trading on Monday following a weaker than expected earnings announcement. The company traded as low as $14.00
Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing
12:33pm, Monday, 02'nd Mar 2026
209,523-share increase in Dyne Therapeutics; estimated transaction value $3.97 million (based on quarterly average pricing) Quarter-end position in Dyne Therapeutics rose $12.82 million in value, refl
Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
07:30am, Monday, 02'nd Mar 2026
- Planned submission for U.S. Accelerated Approval of z-rostudirsen on track for Q2 2026; potential launch in Q1 2027 -
Dyne Therapeutics to Participate in Upcoming Investor Conferences
07:30am, Wednesday, 25'th Feb 2026
WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically drive
